Stock NTRP NEUROTROPE, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Neurotrope, Inc. Stock

Equities

NTRP

US64129T2078

Chart Neurotrope, Inc.

Dynamic Chart

Latest news about Neurotrope, Inc.

Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc. CI
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction. CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1 CI
Neurotrope, Inc. Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease CI
Metuchen Pharmaceuticals LLC entered into a non-binding term sheet to acquire Neurotrope, Inc. from Intracoastal Capital LLC and others for approximately $140 million in a reverse merger transaction. CI
Neurotrope, Inc. intends to spin off Neurotrope Bioscience, Inc. CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Neurotrope, Inc. Announces Board Resignations CI
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial CI
National Institute of Health Awards $2.7 Million Grant to Neurotrope CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
More news

Press releases Neurotrope, Inc.

NEUROTROPE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
NEUROTROPE, INC. : Other Events (form 8-K) AQ
NEUROTROPE, INC. : Other Events, Financial Statements and Exhibits (form 8-K) AQ
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) AQ
NEUROTROPE, INC. : Other Events (form 8-K) AQ
More press releases

Managers and Directors - Neurotrope, Inc.

Managers TitleAgeSince
Alan Tuchman CEO
 Chief Executive Officer 77 -
Daniel Alkon PSD
 President 81 13-08-22
Robert Weinstein DFI
 Director of Finance/CFO 64 13-05-31
Members of the board TitleAgeSince
Alan Tuchman CEO
 Chief Executive Officer 77 -
Ivan Philip Gergel BRD
 Director/Board Member 64 18-12-12
Bruce Bernstein BRD
 Director/Board Member 60 16-11-13
More insiders

Company Profile

Neurotrope, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second-generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. NTRP Stock